Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Lenz on the Updated Findings From the CheckMate-142 Trial in mCRC

June 4th 2020

Heinz-Josef Lenz, MD, FACP, discusses the updated findings from the phase 2 CheckMate-142 trial in previously untreated patients with microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).

Encorafenib Plus Cetuximab Approved in Europe for BRAF V600E-Mutant mCRC

June 3rd 2020

The European Commission has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer who have received prior systemic therapy.

Continued OS Advantage With Encorafenib/Cetuximab Cements Role in BRAF+ mCRC

June 3rd 2020

Scott Kopetz, MD, PhD, FACP, discusses the latest findings from the BEACON CRC study, the importance of testing for BRAF mutations in patients with CRC, and future directions with these agents.

Dr. Andre on the Rationale for the KEYNOTE-177 Trial in mCRC

June 3rd 2020

Thierry Andre, MD, discusses the rationale for the phase 3 KEYNOTE-177 trial in metastatic colorectal cancer.

Dr. Overman on Potential Application of ctDNA in CRC

June 2nd 2020

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

Bekaii-Saab Highlights Targeted Therapy Advances in CRC

June 2nd 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the growing role of targeted therapy in CRC.

Metastatic Gastric Cancer: Recent Advances and Future Directions

June 2nd 2020

Perioperative Strategies in Metastatic Gastric Cancer

June 2nd 2020

Metastatic Gastric Cancer: Promising Later-Line Trials

June 2nd 2020

Metastatic Gastric Cancer: Promising Second-Line Trials

June 2nd 2020

Metastatic Gastric Cancer: Novel Agents Targeting FGF

June 2nd 2020

Gastric Cancer: Frontline Checkpoint Inhibitor Trials

June 2nd 2020

Metastatic Gastric Cancer: Promising Frontline Trials

June 2nd 2020

Emerging Biomarkers in Metastatic Gastric Cancer

June 2nd 2020

Later Lines of Therapy in Metastatic Gastric Cancer

June 2nd 2020

Chemotherapy + Ramucirumab as Second-Line Therapy in mGC

June 2nd 2020

Global Use of Second-Line Therapy in mGC

June 2nd 2020

Metastatic Gastric Cancer: Identifying Disease Progression

June 2nd 2020

Switch Maintenance in Gastric Cancer: Results of JAVELIN Gastric 100

June 2nd 2020

Gastric Cancer: Global Perspectives on Maintenance Therapy

June 2nd 2020